Targeted Molecular Diagnostics

A key aspect of TMD's business model was its focus on tissue-based testing, a crucial component in the development of modern oncology drugs. The company's expertise in biomarker technology enabled its customers to gain a deeper understanding of how their compounds worked and to identify the patient populations in which they were most likely to be effective. This proficiency allowed TMD to assist clients in designing more efficient clinical trials, ultimately aiming to reduce the time and cost associated with bringing novel, targeted cancer therapies to market. At the time of its acquisition, the company supported clinical trials in over 40 countries and offered more than 100 biomarker assays.

A significant milestone in the company's history occurred on November 26, 2008, when it was acquired by Quintiles Transnational Corp., now known as IQVIA. This acquisition was a strategic move for Quintiles to bolster its service offerings in oncology and to integrate TMD's advanced in-house pathology and telepathology capabilities. Following the acquisition, TMD operated as a Quintiles Central Laboratory and expanded its services, including the launch of digital pathology services in Beijing, China, in 2009.